Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.
Status:
Withdrawn
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Phase II study to determine progression free survival (PFS) of nab-paclitaxel administered in
combination with gemcitabine, at two different dose combinations as first line therapy in
patients with unresectable stage IIIB/stage IV non-squamous non-small cell lung cancer
(NSCLC).